Literature DB >> 26746366

Squamous Cell Carcinoma "Transformation" Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas.

Agita Jukna1, Gloria Montanari2, Maria Cecilia Mengoli3, Alberto Cavazza4, Marisa Covi2, Fausto Barbieri5, Federica Bertolini6, Giulio Rossi3.   

Abstract

The authors report two cases of epidermal growth factor receptor gene (EGFR)-mutant stage IV lung adenocarcinomas developing immunohistochemically proven squamous cell carcinoma (SCC) "transformation" concurrently with T790M EGFR mutation, leading to acquired resistance to EGFR inhibitors. Moreover, the histologic change of EGFR-mutant lung adenocarcinoma into SCC has been recently reported in literature. The histological transformation to SCC appears as a novel mechanism of acquired EGFR TKI resistance in EGFR-mutated adenocarcinomas and it may be challenging for treatment.
Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; EGFR; Lung; Squamous cell carcinoma; T790M

Mesh:

Substances:

Year:  2015        PMID: 26746366     DOI: 10.1016/j.jtho.2015.12.096

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  19 in total

Review 1.  Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing.

Authors:  Luisella Righi; Francesca Franzi; Francesca Montarolo; Gaia Gatti; Massimo Bongiovanni; Fausto Sessa; Stefano La Rosa
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Squamous cell carcinoma transformation from adenocarcinoma as an acquired resistance after the EGFR TKI therapy in (EGFR-mutated) non-small cell lung cancer.

Authors:  Shinji Shinohara; Yoshinobu Ichiki; Yukiko Fukuichi; Yohei Honda; Masatoshi Kanayama; Akihiro Taira; Yusuke Nabe; Taiji Kuwata; Masaru Takenaka; Soichi Oka; Yasuhiro Chikaishi; Ayako Hirai; Naoko Imanishi; Koji Kuroda; Kazue Yoneda; Hirotsugu Noguchi; Fumihiro Tanaka
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 3.  Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Authors:  D Westover; J Zugazagoitia; B C Cho; C M Lovly; L Paz-Ares
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

4.  KRAS AND THE REALITY OF PERSONALIZED MEDICINE IN NON-SMALL CELL LUNG CANCER.

Authors:  Havva O Kilgoz; Guzide Bender; Joseph M Scandura; Agnes Viale; Bahar Taneri
Journal:  Mol Med       Date:  2016-07-07       Impact factor: 6.354

Review 5.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

Review 6.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

7.  Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.

Authors:  Hyung Kyu Park; Youjeong Seo; Yoon-La Choi; Myung-Ju Ahn; Joungho Han
Journal:  J Pathol Transl Med       Date:  2017-04-04

8.  EGFR mutations subset in Chinese lung squamous cell carcinoma patients.

Authors:  Ying Sun; Xin Yin; Miao-Miao Wen; Jiao Zhang; Xue-Jiao Wang; Jing-Hua Xia; Yan-Ning Zhang; Zhi-Pei Zhang; Xiao-Fei Li
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

9.  Surgical significance and efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with primary lung adenosquamous carcinoma.

Authors:  Chao Zhang; Haitang Yang; Baoping Lang; Xiangdong Yu; Peng Xiao; Dian Zhang; Liwen Fan; Xiao Zhang
Journal:  Cancer Manag Res       Date:  2018-08-02       Impact factor: 3.989

10.  Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.

Authors:  Rossella Bruno; Agnese Proietti; Greta Alì; Gianfranco Puppo; Alessandro Ribechini; Antonio Chella; Gabriella Fontanini
Journal:  Oncol Lett       Date:  2017-09-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.